

*CJ*  
*Cancel*

wherein:

AP6 is N-(2-phenyl-2-oxoethyl)-2-(2'-pyridine)-pyridinium bromide.

AP2 is N-(2-phenyl-2-oxoethyl)-quinolinium bromide.

AP7 is N-(2-phenyl-2-oxoethyl)-pyrazinium bromide.

YA1 is 2-phenyl-2-oxoethyl-dimethylphosphonate.

YA2 is N-(2-phenyl-2-oxoethyl)-triethylammonium bromide.

AP18 is N-(2-phenyl-2-oxoethyl)-4-tert.-butylpyridinium bromide.

AP24 is N-(2-phenyl-2-oxoethyl)-3-n-butylpyridinium bromide.

34P is pyridine-3,5-dicarboxylic acid.

AP9 is N-(2-phenyl-2-oxoethyl)-4-N,N-dimethylamino-pyridinium bromide.

AP12 is N-(2-phenyl-2-oxoethyl)-pyrazinium bromide.

AP19 is N-(2-phenyl-2-oxoethyl)-3-fluoropyridinium bromide.

AP20 is N-(2-phenyl-2-oxoethyl)-4-ethylpyridinium bromide.

AP23 is N-(2-phenyl-2-oxoethyl)-2,6-dihydroxymethylpyridinium bromide.

AP28 is N-(2-phenyl-2-oxoethyl)-3,5-diiodo-4-pyridinone.

AP5 is N-(2-phenyl-2-oxoethyl)-3,5-dicarboxypyridinium bromide; and this compound

has also been coded PICVA-13.

AP21 is N-(2-phenyl-2-oxethyl)-3,4-dicarboxamide-pyridinium bromide.

AP22 is N-(2-phenyl-2-oxoethyl)-3-bromo-5-carboxypyridinium bromide.--

---


**IN THE CLAIMS:**

Please amend the claims as follows:

Please cancel Claim 2.

Please amend the remaining claims as follows:

*Salt*  
C  
1. (Twice Amended) An ischemia-damage mitigating salt of a compound having a formula I:



I

wherein R and R<sub>1</sub> are independently hydrogen, sulfamide, carboxyamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate, or halide (Br, Cl, I, F), wherein at least one of R and R<sub>1</sub> is COOH, wherein R<sub>2</sub> and R<sub>3</sub> are independently hydrogen, sulfamide, carboxyamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate or halide (Br, Cl, I, F), wherein R and R<sub>1</sub> are meta to each other and to the heteroatom.


C4  
2. (Amended) The ischemia-damage mitigating salt of claim 1 wherein R<sub>2</sub> and R<sub>3</sub> are both hydrogen.

3. (Amended) The ischemia-damage mitigating salt of claim 1 wherein R and R<sub>1</sub> are each COOH, and R<sub>2</sub> and R<sub>3</sub> are both hydrogen.

7. (Amended) The ischemia-damage mitigating salt of claim 1 wherein the compound is selected from the group consisting of 1-phenacyl-2,3-dicarboxypyridinium bromide; 1-phenacyl-2,4-dicarboxypyridinium bromide; 1-phenacyl-2,5-dicarboxypyridinium bromide; 1-phenacyl-3,5-dicarboxypyridinium bromide (AP5); 1-phenacyl-2,6-dicarboxypyridinium bromide; 1-phenacyl-2,3-dicarboxyimidepyridinium bromide; 1-phenacyl-2,4-dicarboxyimidepyridinium

bromide; 1-phenacyl-2,5-dicarboxyimidepyridinium bromide; and 1-phenacyl-2,6-dicarboxyimidepyridinium bromide.

8. (Amended) A pharmaceutical composition comprising a salt of a compound from formula I in a pharmaceutically acceptable carrier, wherein formula I comprises:




wherein R and R<sub>1</sub> are independently hydrogen, sulfamide, carboxamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate, or halide (Br, Cl, I, F), wherein at least one of R and R<sub>1</sub> is COOH, wherein R<sub>2</sub> and R<sub>3</sub> are independently hydrogen, sulfamide, carboxamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate, or halide (Br, Cl, I, F).

14. (Amended) The pharmaceutical composition of claim 8 wherein the compound is selected from the group consisting of 1-phenacyl-2,3-dicarboxypyridinium bromide; 1-phenacyl-2,4-dicarboxypyridinium bromide; 1-phenacyl-2,5-dicarboxypyridinium bromide; 1-phenacyl-3,5-dicarboxypyridinium bromide (AP5); 1-phenacyl-2,6-dicarboxypyridinium bromide; 1-phenacyl-2,3-dicarboxyimidepyridinium bromide; 1-phenacyl-2,4-dicarboxyimidepyridinium

bromide; 1-phenacyl-2,5-dicarboxyimidepyridinium bromide; and 1-phenacyl-2,6-dicarboxyimidepyridinium bromide.

*CS* *Amplify* *15* 25. (Amended) A method for inhibiting tissue damage caused by ischemia, comprising administering an effective amount of a salt of a compound of formula I, wherein formula I comprises:



I

wherein R and R<sub>1</sub> are independently hydrogen, sulfamide, carboxamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight, or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate, or halide (Br, Cl, I, F), wherein at least one of R and R<sub>1</sub> is COOH, wherein R<sub>2</sub> and R<sub>3</sub> are independently hydrogen, sulfamide, carboxamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate, or halide (Br, Cl, I, F).


*CS* *26* 26. (Amended) The method of claim 15 wherein the compound is selected from the group consisting of 1-phenacyl-2,3-dicarboxypyridinium bromide; 1-phenacyl-2,4-dicarboxypyridinium bromide; 1-phenacyl-2,5-dicarboxypyridinium bromide; 1-phenacyl-3,5-dicarboxypyridinium bromide (AP5); 1-phenacyl-2,6-dicarboxypyridinium bromide; 1-phenacyl-2,3-dicarboxyimidepyridinium bromide; 1-phenacyl-2,4-dicarboxyimidepyridinium bromide; 1-

*Cy  
Conc*

phenacyl-2,5-dicarboxyimidepyridinium bromide; and 1-phenacyl-2,6-dicarboxyimidepyridinium bromide.

Please add the following additional claims 28-32:

--28. (New) An ischemia-damage mitigating compound or salt thereof, said compound having a formula I:



wherein R and R<sub>1</sub> are independently hydrogen, sulfamide, carboxyamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitrate, or halide (Br, Cl, I, F), wherein both R and R<sub>1</sub> cannot be hydrogen, wherein R<sub>2</sub> and R<sub>3</sub> are independently hydrogen, sulfamide, carboxyamide, cyano, straight or branched C<sub>1-6</sub> alkyl, straight or branched C<sub>2-6</sub> alkenyl, straight or branched C<sub>1-6</sub> alkoxy, a straight chain C<sub>1-6</sub> alkyl or a straight chain C<sub>2-6</sub> alkenyl having an ether link or an ester link, toluenyl, COOH, nitride or halide (Br, Cl, I, F),

with the proviso that if either R or R<sub>1</sub> is CH<sub>3</sub>, the other is not H; and

with the further proviso that if either of R or R<sub>1</sub> is 2-methyl, the other is not 4-alkoxycarbonyl.